肾脏原发性恶性纤维组织细胞瘤1例报告

患者，男，76岁。无痛性血尿2周。B超及CT检查均示左肾上极占位性病变。临床诊断为左肾肾癌而行左肾切除术．送检标本大体检查：肾脏体积10．0cm×5．0cm×4．5cm，连带输尿管长8．0cm。剖开肾脏，在其上极可见一灰白灰黄相间的实性肿块，呈5．2cm×4．5cm×4．0cm大小，无明显包膜，质地中等偏硬。另送“肾动脉及腹主动脉旁”淋巴结2枚，直径1．8～3．0cm，切面呈灰白，质硬。显微镜检查：肿瘤由多形细胞、校形细胞及组织细胞样细胞组成。多形细胞异形明显，胞浆丰富，呈粉红色细颗粒状或泡沫状，核呈肾形或分叶状，巨核、多枚及怪异校也…     

肝脏恶性纤维组织细胞瘤11例临床分析

目的 探讨肝脏恶性纤维组织细胞瘤(MFH)准确临床诊断和合理治疗的方法.方法 回顾性分析我院2000年2月至2009年7月间11例经手术切除并经病理证实的肝脏MFH患者的临床资料.结果 大多数MFH患者无明显症状,血清学检查正常,9例患者MRI、CT有一定的特征性表现.全部患者手术并发症发生率为9%,无手术死亡.随访发现8例患者术后1年复发.结论 MFH侵袭性强,复发率高,病理分级差,CT、MRI有一定的诊断价值,手术完整切除是MFH首选的治疗方法,术后辅以放疗等有助于提高患者的远期生存率.     

原发性乳腺恶性纤维组织细胞瘤1例报告

患者,女,36岁.因右侧乳腺肿块切除术后4年,发现右乳房肿块伴胀痛10个月入院.患者4年前因右乳纤维腺瘤曾行肿块切除术,术后恢复良好.     

结直肠恶性纤维组织细胞瘤1例并文献复习

目的报道1例直肠恶性纤维组织细胞瘤（malignant fibrous histiocytoma,MFH）并复习文献,提高对该病的认识。方法报道并回顾性分析我院收治的1例结直肠恶性纤维组织细胞瘤患者,采用Miles手术方式,完整切除肿瘤,并进行镜下和免疫组化检查和随访。结果患者术后半年出现会阴部肿物,经穿刺活检为恶性纤维组织细胞瘤转移。结论MFH通常采用外科手术治疗,但术后局部复发和转移率非常高,预后较差。联合放化疗的疗效仍然不清楚,有待进一步深入研究。     

肾脏原发性恶性纤维组织细胞瘤三例报告

恶性纤维组织细胞瘤 (MFH)原发于肾脏者罕见。我们自 1997年 4月至2 0 0 1年 5月收治 3例 ,现报告如下。例 1,女 ,2 3岁。 1997年 4月住院。持续性低热、进行性消瘦伴左上腹胀痛1个月 ,无血尿及尿路刺激症状。查体 :T 37.9℃ ,心肺未见异常 ,左肋缘下可触及 10cm× 8cm× 6cm包块 ,质硬 ,不光滑 ,无明显压痛 ,活动尚可 ,实验室检查 :血常规 :WBC 6 .8G/L ,血沉 (ESR) 4 0mm/ 1h、5 5mm/ 2h。B超示左肾中下极11.5cm× 8.5cm× 6 .0cm密度不均匀的实质肿物 ,仅上极残留少许肾组织。IVU示中下组肾盏未显影 ,上组肾盏呈向上受压移位改变…     

肾脏恶性纤维组织细胞瘤二例报告

例1 男,56岁.因乏力、纳差3个月,低热1个月,于1988年3月5日人院.既往无腰痛、血尿、膀胱刺激征.体检:右肋缘下触及 4cm×5cm肿块,质硬,活动,表面不平.B超示右肾14.8cm×8.5cm×8.7cm,中下部探及8.5cm×9.0cm肿块.边界尚清晰,未见完整包膜,内部回声不均匀.腹部平片示右肾区L_2平面数枚点状钙化,右肾轮廓不清.静脉尿路造影示右肾盂肾盏形态不规则,下盏受压,向上移位.CT报告右肾增大、变形,除上极少许正常肾组织外,大多为肿瘤占据.肿块9.5cm×8.2cm×12.0cm,密度不均,有部分钙化灶及坏死液化区,无明显增强效应,部分断层可见病变与腰大肌粘连.血     

乳房恶性纤维组织细胞瘤一例

病例:女,61岁,无意中发现左侧乳房肿块,自觉逐渐增大且伴有压痛,来我院就诊.查体:左乳外上象限可扪及一肿块,大小为4.0 cm×3.0 cm,其表面有一直径1.0 cm血肿.有轻度压痛,活动度尚可,皮肤表面无红肿、无破溃,腋下未及明显肿大淋巴结.B超示:双乳小叶增生,左乳低回声团块大小4.0 cm×1.4 cm,内部回声不均,内可见血流信号伴直径0.4 mm回声团块,左腋下及一枚大小1.5 cm×0.8 cm淋巴结.     

肾盂原发性恶性纤维组织细胞瘤1例报告并文献复习

目的：探讨肾盂原发性恶性纤维组织细胞瘤（Malignant fibrous histiocytoma,MFH）的临床特点和诊治方法。方法：对1例MFH患者行根治性肾切除＋肾静脉癌栓切除＋周围淋巴结清扫术。结果：术后病理报道左肾盂恶性纤维组织细胞瘤伴肾静脉癌栓。结论：术后应终身定期随访．如复发则相应积极治疗,从而能使部分患者有机会长期存活。     

Primary pulmonary malignant meningioma

Primary pulmonary meningiomas are relatively rare and mostly benign. To exclude pulmonary metastasis of an intracranial meningioma, imaging studies of the brain should be performed. We believe that only one primary pulmonary malignant meningioma in which a metastasis from the brain was excluded has been reported. In this report we describe a second case with malignant features.     

Primary anorectal malignant melanoma

A case of primary anorectal malignant melanoma seen in a 46 year old woman is presented herein. Her most marked symptoms were bloody stools and anal pain. Endoscopic examination indicated a tumor with ulceration but without pigmentation in the anorectal region. Histologic examination of the biopsied specimens showed spindle-shaped cells with atypia proliferating in a bandlike arrangement, as in leiomyosarcoma. An abdominoperineal resection was done and detailed histological examination of the tumor comfirmed the nature of the tumor to be malignant melanoma. The postoperative immunochemotherapy consisted of Dimethyl-Triazeno-Imidasole-Carboxamide (DTIC), Amino-Methyl-Pyrimidinyl-Methyl-Chlorethyl-Nitrosourea-Hydrochloride (ACNU), Vincristine (VCR) and OK-432. The patient has been well without recurrence for fifteen months following her operation through the continuous administration of these agents.     

Primary intestinal posttransplant T-cell lymphoma

There have been only five reported cases of primary posttransplant T-cell lymphoma. We report the first case associated with the use of sirolimus (Rapamycin, Wyeth-Ayerst, Philadelphia, PA). The patient, receiving prednisone, cyclosporine, and sirolimus treatment, developed ascites, diarrhea, and weight loss 7 months after his second renal transplant. Tissue obtained at laparotomy established the diagnosis of primary T-cell lymphoma. Latent membrane protein-1 for Epstein-Barr virus was negative, but in-site hybridization test for Epstein-Barr-encoded RNA was positive. Despite aggressive chemotherapy, the patient died 8 months posttransplant. This is the sixth reported case of primary intestinal posttransplant T-cell lymphoma, but it is the first case associated with the use of sirolimus. The incidence of posttransplant lymphoproliferative disease in patients receiving sirolimus should be studied.     

Non-operative management of malignant intestinal obstruction

Intestinal obstruction is a relatively common clinical problem in patients with advanced cancer, particularly those with colorectal and ovarian tumours. A proportion of patients have a non-malignant cause for their obstruction, but in the remaining patients obstruction will be caused by advanced malignancy itself. In the past, most patients were either managed surgically or by nasogastric intestinal decompression and intravenous hydration. Surgery in patients with advanced cancer is associated with high mortality and morbidity. Effective surgical decompression is difficult. We have managed 24 patients with advanced abdominal malignancy and previous operative or radiological evidence of intestinal obstruction without operation. The technique is only appropriate for patients in whom a solitary or correctable obstructing lesion can be excluded. The patient is encouraged to take free fluid and a diet low in fibre. Intestinal colic is managed with morphine, the dose required being titrated for each individual patient against background pain and colic. Vomiting is controlled by the parenteral administration of antiemetic drugs. To simplify drug administration, morphine and metoclopramide are mixed in the same syringe and infused subcutaneously simultaneously. In our 24 patients the mean survival rate after the onset of complete obstruction was 29.2 days. The mean dose of morphine infused was 9.2 mg/h, and the mean dose of metoclopramide was 6.9 mg/h. The case of an 82-year-old male patient is presented. We commend the technique to surgeons contemplating surgery in these very difficult patients. It is simple, relatively non-invasive and saves the patients the pain, discomfort and complications of unproductive surgery.     

Primary malignant large bowel lymphoma

Primary gastrointestinal (GI) lymphomas constitute about 5.6 per cent of total gut neoplasms. The involvement of large bowel as primary site is all the more rare. We carried out this study to evaluate the prevalence and clinicopathological features of large bowel lymphoma at Gujarat Cancer and Research Institute and to compare our findings with published literature. We carried out a retrospective analysis of the records of histologically diagnosed cases of large bowel lymphoma over a 5 year period. A total of eight cases of large bowel lymphoma were identified compared with 57 cases of primary GI lymphoma of other sites, constituting about 12.3 per cent (eight of 65) of all GI lymphomas. Peak incidence was observed in the second decade of life with a mean age at presentation of 30.6 years (range 4-70 years). A male-to-female ratio of one to two was observed. The most commonly presenting feature was altered bowel habits and diarrhea in more than 50 per cent of the patients. One patient presented with acute intestinal obstruction. Diagnosis was made by colonoscopic biopsies in all but one case. All of the patients were treated with surgery and adjuvant chemotherapy. A 4-year disease-free survival of 66.7 per cent was observed (95% confidence interval 0.05-1.28). There was no significant difference in survival in patients with high-grade versus low-grade tumors (50% vs 66.7%; P = 0.88) and stage of disease (75% vs 50%; P = 0.45) in stage II and III respectively. We conclude that large bowel lymphoma is a curable disease if treated aggressively. We suggest that all patients should be treated by primary surgery and should receive adjuvant chemotherapy.     

Primary renal malignant fibrous histiocytoma

The ninth case of a primary renal malignant fibrous histiocytoma to appear in the English literature is described. The patient underwent preoperative renal artery embolization followed by radical nephrectomy and adjuvant chemotherapy. While adjuvant chemotherapy has prolonged the disease free interval and improved the survival rates for patients with tumor arising at other sites, its use in our patient did not prevent the development of metastasis and the patient's early death.